Top 100 biotech ven­ture in­vestors; Bris­tol My­ers’ IL-12 breakup; Sci­en­tif­ic twist of fate; Track­ing bio­phar­ma lay­offs; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Thanks for read­ing. This week is ex­tra spe­cial — and not just be­cause of the Su­per Bowl — as it marks the 100th edi­tion of the End­points Week­ly. I’d love to hear from you on what you like about this re­port — and what you think could be bet­ter. You can al­ways re­ply to this email to get in touch. (Cor­rec­tion note: In last week’s email, I mis­tak­en­ly wrote that Bris­tol My­ers Squibb aban­doned two “pep­tide-masked” CT­LA-4 pro­grams. On­ly one of the two dis­con­tin­ued CT­LA-4 pro­grams was pep­tide-masked.)

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER